CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review.
CDK4/6 inhibitors
adverse events
breast cancer
cardiotoxicity
therapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
06
2023
accepted:
18
09
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Breast cancer is characterized by the uncontrolled proliferation of breast cells, with a high incidence reported in 2020 to have affected over 2 million women. In recent years, the conventional methods of treating breast cancer have involved radiotherapy and chemotherapy. However, the emergence of CDK4/6 inhibitors has shown potential as a promising cancer therapy. Cyclin-dependent kinases (CDK) inhibitors are a class of molecules that impede the formation of an active kinase complex, thereby hindering its activity and consequently halting the progression of the cell cycle. It was discovered that they have a significant impact on impeding the progression of the cancer. This is evident with the Food and Drug Administration's approval of drugs such as palbociclib, ribociclib, and abemaciclib for hormone receptor-positive metastatic breast cancer in combination with specific endocrine therapies. In spite of enormous success in breast cancer treatment, certain obstacles have emerged, such as therapy resistance, side effects, and most of all, cardiotoxicity. Some of these drawbacks have been successfully overcome by dosage reduction, different combinations of the drugs, and the assessment of each patient's condition and suitability prior to treatment. Yet other drawbacks still require tenacious research, especially certain cases of cardiotoxicities. This article delves into the biological mechanisms of CDK4/6 in the cell cycle and cancer, as well as the clinical advantages and most common adverse events (AEs) associated with CDK4/6 inhibitors. The primary objective of this review is to provide a comprehensive analysis of cardiotoxic AEs and elucidate the underlying pathophysiological mechanisms responsible for the cardiotoxicity of CDK4/6 inhibitors.
Identifiants
pubmed: 37841752
doi: 10.1177/17588359231205848
pii: 10.1177_17588359231205848
pmc: PMC10571689
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359231205848Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Eur Heart J. 2013 Apr;34(15):1102-11
pubmed: 22789916
Drugs. 2021 Feb;81(3):317-331
pubmed: 33369721
Breast Cancer. 2020 May;27(3):340-346
pubmed: 32043218
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
Cardiol Clin. 2019 Nov;37(4):407-418
pubmed: 31587782
BioDrugs. 2019 Dec;33(6):613-620
pubmed: 31529317
Front Pharmacol. 2021 Oct 28;12:769315
pubmed: 34776981
Front Cardiovasc Med. 2021 Feb 23;8:638895
pubmed: 33732735
Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202
pubmed: 31369120
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
Methods Mol Biol. 2005;296:113-53
pubmed: 15576929
Breast Cancer Res Treat. 2019 Apr;174(3):597-604
pubmed: 30659432
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Target Oncol. 2015 Mar;10(1):45-53
pubmed: 24595903
Breast. 2021 Jun;57:5-17
pubmed: 33677313
Chem Res Toxicol. 2020 Jan 21;33(1):125-136
pubmed: 31840498
Clin Cancer Res. 2018 Jul 1;24(13):2999-3004
pubmed: 29437768
JAMA Netw Open. 2019 Aug 2;2(8):e198890
pubmed: 31397860
Heart Fail Rev. 2021 Jul;26(4):919-935
pubmed: 33405000
Tex Heart Inst J. 2011;38(3):246-7
pubmed: 21748048
Oncogene. 2014 Apr 10;33(15):1890-903
pubmed: 23644662
Front Cardiovasc Med. 2023 Feb 22;10:1078135
pubmed: 36910540
J Chiropr Med. 2006 Autumn;5(3):101-17
pubmed: 19674681
J Biol Chem. 2001 May 18;276(20):16617-23
pubmed: 11278443
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Anticancer Drugs. 2018 Mar;29(3):271-280
pubmed: 29360661
J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drug:e93-e104
pubmed: 27755247
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Curr Heart Fail Rep. 2012 Jun;9(2):117-27
pubmed: 22382639
Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88
pubmed: 34508254
Nat Rev Cardiol. 2015 Sep;12(9):547-58
pubmed: 25962976
Oncotarget. 2015 Apr 20;6(11):8525-38
pubmed: 25940700
Breast Care (Basel). 2022 Jun;17(3):330-335
pubmed: 35957944
Curr Treat Options Oncol. 2019 May 25;20(7):55
pubmed: 31129799
Cell Cycle. 2006 Dec;5(23):2760-8
pubmed: 17172845
Expert Rev Anticancer Ther. 2019 Jul;19(7):569-587
pubmed: 31219365
Anticancer Res. 2020 Sep;40(9):4829-4841
pubmed: 32878771
Med Sci (Basel). 2022 May 25;10(2):
pubmed: 35736347
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Clin Breast Cancer. 2016 Feb;16(1):8-17
pubmed: 26303211
J Am Heart Assoc. 2014 Apr 22;3(2):e000665
pubmed: 24755151
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Cancer Treat Rev. 2018 Feb;63:135-143
pubmed: 29304463
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
N Engl J Med. 2022 Mar 10;386(10):942-950
pubmed: 35263519
J Natl Cancer Inst. 2000 Mar 1;92(5):376-87
pubmed: 10699068
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
BMC Pharmacol Toxicol. 2016 Mar 10;17:12
pubmed: 26960809
Cell Syst. 2016 Jan 27;2(1):8-10
pubmed: 27136683
Cancers (Basel). 2022 Sep 25;14(19):
pubmed: 36230587
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Pharmacogenomics J. 2018 Apr;18(2):215-226
pubmed: 28719597
Acta Pharmacol Sin. 2021 Feb;42(2):171-178
pubmed: 32504067
Clin Cancer Res. 2016 Apr 15;22(8):2000-8
pubmed: 26631614
Am J Cancer Res. 2021 May 15;11(5):1913-1935
pubmed: 34094661
Semin Cancer Biol. 2023 Jan;88:106-122
pubmed: 36565895
J Clin Oncol. 2008 Nov 10;26(32):5204-12
pubmed: 18838713
Oncogene. 2016 Sep 15;35(37):4829-35
pubmed: 26923330
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899866
Front Cardiovasc Med. 2021 Nov 19;8:758010
pubmed: 34869670
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Pharmacogenomics J. 2012 Apr;12(2):165-72
pubmed: 20921969
Pharmacol Ther. 2018 Sep;189:89-103
pubmed: 29698683
Cancer Cell Int. 2017 Mar 6;17:35
pubmed: 28286417
Europace. 2009 Dec;11(12):1579-86
pubmed: 19801562
Life (Basel). 2020 Dec 11;10(12):
pubmed: 33322351
Clin Med Insights Cardiol. 2019 Jul 29;13:1179546819866445
pubmed: 31384135
Cancer Treat Rev. 2021 Nov;100:102282
pubmed: 34438238
Oncol Lett. 2014 May;7(5):1673-1678
pubmed: 24765199
Korean J Radiol. 2015 Mar-Apr;16(2):304-13
pubmed: 25741192
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Basic Clin Pharmacol Toxicol. 2010 Jul;107(1):614-8
pubmed: 20406211
Curr Oncol Rep. 2015;17(5):443
pubmed: 25716100
Drug Des Devel Ther. 2022 Mar 16;16:727-735
pubmed: 35321498
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
Leukemia. 2020 Aug;34(8):2184-2197
pubmed: 32060403
Hypertension. 2012 Sep;60(3):607-15
pubmed: 22851729
Cardiovasc Toxicol. 2017 Oct;17(4):487-493
pubmed: 28861837
Int J Mol Sci. 2022 Mar 04;23(5):
pubmed: 35269958
Clin Cancer Res. 2012 Jan 15;18(2):568-76
pubmed: 22090362
Eur J Med Chem. 2017 Dec 15;142:424-458
pubmed: 28911822
Dev Cell. 2004 Mar;6(3):321-7
pubmed: 15030756
Drugs. 2018 Sep;78(13):1353-1362
pubmed: 30143968
Support Care Cancer. 2022 Nov;30(11):9071-9078
pubmed: 35972646
Res Integr Peer Rev. 2019 Mar 26;4:5
pubmed: 30962953
Am J Transl Res. 2019 Jun 15;11(6):3481-3489
pubmed: 31312360
Biochim Biophys Acta Mol Cell Res. 2022 Dec;1869(12):119346
pubmed: 36030016
Breast Cancer Res Treat. 2019 Aug;176(3):483-494
pubmed: 31065872
Pharmacotherapy. 2010 Jul;30(7):684-701
pubmed: 20575633
Adv Exp Med Biol. 2020;1257:181-192
pubmed: 32483740
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Toxicol Appl Pharmacol. 2010 Apr 15;244(2):190-5
pubmed: 20045709
Lancet. 2007 Dec 15;370(9604):2011-9
pubmed: 18083403
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Breast Cancer Res Treat. 2019 Sep;177(2):237-250
pubmed: 31165940
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Br J Cancer. 2021 Jan;124(1):13-26
pubmed: 33239679
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
World J Gastroenterol. 2019 Aug 7;25(29):3870-3896
pubmed: 31413525
Expert Opin Investig Drugs. 2011 Dec;20(12):1611-28
pubmed: 22017180
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
Curr Treat Options Cardiovasc Med. 2015 Dec;17(12):60
pubmed: 26490280
Drug Saf. 2013 May;36(5):295-316
pubmed: 23620167
Ann Oncol. 2021 Apr;32(4):488-499
pubmed: 33385521
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
Pharmacogenomics. 2005 Apr;6(3):259-70
pubmed: 16013957
Mol Cancer Ther. 2020 Jan;19(1):3-12
pubmed: 31909732
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Oncogene. 2009 Aug 20;28(33):2925-39
pubmed: 19561645
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Breast Cancer Res Treat. 2021 Feb;186(1):219-227
pubmed: 33150548
Cancer. 2012 Apr 15;118(8 Suppl):2270-6
pubmed: 22488701
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
Curr Heart Fail Rep. 2020 Dec;17(6):397-408
pubmed: 32979150
Drug Saf. 2015 Oct;38(10):855-67
pubmed: 26108299
Biochem Pharmacol. 2018 Aug;154:10-17
pubmed: 29673999
Clin Cancer Res. 2014 Jul 1;20(13):3379-83
pubmed: 24795392
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568
J Glob Oncol. 2017 Apr 11;3(4):289-303
pubmed: 28831437
Results Probl Cell Differ. 2011;53:365-89
pubmed: 21630153
Acta Oncol. 2009;48(1):9-17
pubmed: 18752081
Toxicol Pathol. 2006;34(1):81-90
pubmed: 16507548
Cardiovasc Res. 2019 Apr 15;115(5):966-977
pubmed: 30629146
Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451
pubmed: 30038670
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882